secretion is very different between younger and older subjects.
Accuracy of Genotyping of Single-Nucleotide Polymorphisms by PCR-ELISA Allele-specific Oligonucleotide Hybridization Typing and by Amplification Refractory Mutation System, Julian C. Knight Early methods for the detection of single-nucleotide polymorphisms (SNPs) were based on restriction fragment length polymorphism analysis (1 ) and the effects of base-pair changes on DNA fragment melting temperatures (denaturing gradient gel electrophoresis) (2 ) . More recently, detection techniques have utilized allele-specific oligonucleotide (ASO) hybridization (3, 4 ) , the singlestranded conformational polymorphism method (5 ), allele-specific priming of PCR (6, 7 ) , primer-guided nucleotide incorporation assays (8 ) , and oligonucleotide ligation assays (9 ) .
The technique of differential hybridization to ASO probes has been widely used. Under high stringency conditions, synthetic DNA probes will only anneal to their complementary target sequences in the sample DNA if they are perfectly matched, with a single base-pair mismatch sufficient to prevent formation of a stable probe-target duplex (10, 11 ) . PCR-amplified genomic DNA products are applied to nylon filters as a series of "dot blots" to which radiolabeled ASOs are hybridized (4 ) . The reverse approach can also be used with ASO probes fixed to a membrane support (12 ) or in a microtiter plate format (13 ) . A combination of PCR amplification with allele-specific hybridization in a microtiter plate format using colorimetric ELISA-based detection was developed (PCR-ELISA ASO typing) that provided highly sensitive and quantitative detection; this method was initially applied to HLA typing (14, 15 ) . The PCR-ELISA ASO typing method amplifies the number of copies of a DNA segment from a sample of genomic DNA by PCR with the incorporation of digoxigenin-11-dUTP. Samples are analyzed in a microtiter plate format by alkaline denaturation and hybridization to biotinylated allelespecific capture probes bound to streptavidin-coated plates. The hybridized DNA is detected by ELISA, using anti-digoxigenin horseradish peroxidase conjugate and the colorimetric substrate 2,2Ј-azino-di-(3-ethylbenzthiazolinsulfonate) (14 ) .
Detection of SNPs by allele-specific PCR, also known as the amplification refractory mutation system (ARMS), utilizes a primer with a 3Ј mismatch at the position of the variable nucleotide together with another primer complementary to both alleles. When the mismatch occurs, 3Ј elongation by Taq polymerase is prevented, making amplification inefficient with preferential amplification of the perfectly matched allele. This avoids the need for probe hybridization, ligation, or restriction enzyme cleavage steps. The PCR products are visualized on an ethidium bromide-stained agarose gel. Careful optimization of the concentrations of magnesium, oligonucleotide, dNTP, Taq polymerase, and DNA used; the PCR cycling conditions; and the design of the ASO is needed to ensure high specificity (16 ) .
To assess the accuracy of the PCR-ELISA ASO typing and ARMS genotyping techniques in large-scale casecontrol studies, we compared these methods with direct DNA sequencing of genomic DNA. Direct automated fluorescent DNA cycle sequencing using mutant Taq FS DNA polymerase with dye-labeled primers provides a very high-fidelity sequence that reproducibly identifies heterozygous individuals for a given SNP (17, 18 ) . This method was used as the gold standard against which the sensitivity and specificity of the genotyping methods was compared. Biallelic SNPs at Ϫ238 nt (TNF Ϫ238 ) (19 ) and Ϫ376 nt (TNF Ϫ376 ) (20 ) relative to the transcriptional start site of the tumor necrosis factor (TNF) promoter were genotyped in two large malaria case-control studies carried out in African populations (21, 22 ) . This included a study from Kenya in which the results of direct sequencing and PCR-ELISA ASO typing were available for over 500 individuals, allowing a direct comparison of the accuracy of the PCR-ELISA technique. A second study in The Gambia included genotyping data by PCR-ELISA ASO and ARMS techniques: these were compared and where they differed, the cases were directly sequenced, allowing a comparison of the two techniques.
Genomic DNA was amplified by nested PCR to generate a digoxigenin-labeled product spanning Ϫ558 to Ϫ183 nt of the TNF promoter region. The first round of amplification used primers 5Ј-GGAAGAGAACCTGCCTG-GCA-3Ј (Ϫ948 to Ϫ929 nt) and 5Ј-GTTACAGGAGAC-CTCTGGGG-3Ј (ϩ130 to ϩ111 nt); cycling conditions were 94°C for 12 min, followed by 35 cycles of 94°C for 30 s, 58°C for 45 s, 72°C for 1 min, and then 10 min at 72°C after the final cycle. Nested PCR to incorporate digoxigenin used PCR DIG labeling mixture (Boehringer Mannheim) with primers 5Ј-TTTCCTGAGGCCT-CAAGCCT-3Ј (Ϫ558 to Ϫ539 nt) and 5Ј-GTTGGGGACA-CACAAGCATC-3Ј (Ϫ183 to Ϫ202 nt). Cycling conditions were 94°C for 12 min, followed by 25 cycles at 94°C 30 s, 58°C for 30 s, 72°C for 45 s, and then 10 min at 72°C after the final cycle. G3 A substituted digoxigenin-labeled PCR products were detected using a PCR ELISA kit (Boehringer Mannheim). PCR products were alkaline denatured and then hybridized in streptavidin-coated microtiter plates with specific 5Ј-biotinylated oligonucleotide probes at 55°C for 2 h. The capture probes used were 5Ј-CCTCGGAATCGGAGCAGGGA-3Ј (Ϫ248 to Ϫ229 nt) and 5Ј-CCTCGGAATCAGAGCAGGGA-3Ј at 2.5 nmol/L for TNF Ϫ238 ; and 5Ј-CTGTCTGGAAGTTAGAAGGA-3Ј (Ϫ386 to Ϫ367 nt) and 5Ј-CTGTCTGGAAATTA-GAAGGA-3Ј at 15 nmol/L for TNF Ϫ376 . Hybridized probe immobilized on the streptavidin-coated wells was labeled by incubation of 2 milliunits of anti-digoxigenin peroxi- (21 ) . Briefly, genomic DNA was amplified using a conserved primer 5Ј-CCGGATCATGCTTTCAGTGC-3Ј together with sequence-specific primers for either the TNF Ϫ238 G allele (5Ј-AGACCCCCCTCGGAATCG-3Ј) or the TNF Ϫ238 A allele (5Ј-AAGACCCCCCTCGGAATCA-3Ј). Primers generating a 266-bp fragment of the ␤ 2 -microglobulin gene were used as a positive control (5Ј-CCAAAGAT-TCAGGTTTACTCACG-3Ј and 5Ј-ACTTAACTATCTT-GGGCTGTGAC-3Ј) in each reaction mixture. Cycling conditions were as follows: 95°C for 10 min; followed by 5 cycles of 95°C for 1 min, 67°C for 1 min, 72°C for 1 min; then 25 cycles of 95°C for 1 min, 62°C for 1 min, 72°C for 1 min, followed by a final 10 min at 72°C. The products were resolved in 2% agarose gels, stained with ethidium bromide, and visualized under ultraviolet light.
Genomic DNA was PCR amplified using primers (complementary sequence underlined) tagged with M13 tails ( 5 Ј -T G T A A A A C G A C G G C C A G T T T T C C T G A G -GCCTCAAGCCT-3Ј
) and (5ЈCAGGAAACAGCTATGAC-CGTTGGGGACACACAAGCATC-3Ј) and then cycle sequenced using the ABI PRISM Big Dye Primer ready reaction kit (Perkin-Elmer) with the Ϫ21M13 forward primer. Products were analyzed on an ABI 377 automated sequencer. The PCR-ELISA and ARMS techniques were analyzed in terms of their accuracy of detection of the rarer A allele (cases in which an individual was homozygous for the A allele were combined with the total number heterozygous for the polymorphism).
The results of PCR-ELISA ASO typing of TNF Ϫ238 and TNF Ϫ376 in 565 individuals from a Kenyan population were compared with the genotypes determined by direct DNA sequencing (Table 1A ). The distribution of alleles among case and control groups was consistent with Hardy-Weinberg equilibrium predictions. Data are presented first for genotype allocation based on the ELISA data. This gave genotyping results for TNF Ϫ238 that were highly specific (98.8%), but the sensitivity was lower, 91.3%. This was increased at the time of genotyping by direct sequencing 5% of samples (28 of 565) in which the PCR-ELISA data were potentially ambiguous. This increased the sensitivity to 94.5% and the specificity to 100%. For a second SNP, TNF Ϫ376 , the results of PCR-ELISA ASO genotyping were also highly specific (100%) and sensitive (93.9%). The number of cases in which results were potentially ambiguous and required confirmation by direct sequencing was fewer (1.8% of samples genotyped) and the resulting increase in accuracy was small.
Data were available for 1109 individuals from a casecontrol study in The Gambia in whom genotyping by the PCR-ELISA ASO technique was compared with ARMS (Table 1B) . A high degree of concordance was seen between the two methods, with agreement in 97% of individuals typed. Where the methods differed in the genotype found, results were compared with the genotype derived by direct sequencing. Cases in which the PCR-ELISA and ARMS methods gave the same genotyping results were considered correctly typed. Both PCR-ELISA and ARMS were highly specific in their detection of the TNF Ϫ238A allele (99.6% and 99.5%, respectively). The sensitivity of both genotyping techniques was lower: 95.3% for PCR-ELISA ASO typing and 89.5% for ARMS. This analysis represents one of the largest studies of the accuracy of SNP detection in population-based genetic studies. We conclude that both the PCR-ELISA ASO typing and ARMS offer highly specific and sensitive detection of SNPs by methods that can be performed using widely available laboratory apparatus.
The PCR-ELISA ASO typing method combines the sensitivity of nucleic acid amplification and the high specificity of hybridization protocols with a nonisotopic quantification method that is itself highly sensitive and specific. The technique was used to genotype two SNPs of the TNF promoter region in 565 individuals, and the sensitivity and specificity of the method were determined by comparison with results of direct sequencing. This demonstrated that the typing method was highly specific and sensitive for detection of SNPs in the TNF promoter region. For one of these SNPs, TNF Ϫ238 , sequencing of a small number of potentially ambiguous samples at the time of genotyping was useful in terms of a modest increase in sensitivity. The ARMS technique showed a high degree of concordance with the PCR-ELISA ASO typing results, although its sensitivity was lower.
The accuracy of SNP detection by PCR-ELISA ASO typing is consistent with previous reports demonstrating the accuracy of the technique for HLA typing (23 ) . Disadvantages of PCR-ELISA ASO typing include its relatively high cost ($0.81 per genotype for PCR-ELISA ASO typing compared with $0.39 for ARMS) and the fact that although it has the potential for automation, it remains labor intensive. The application of robotic technology to typing methods such as the oligonucleotide ligation assay using fluorescence-based analysis has allowed large-scale automated SNP detection (24 ) . However, until such methods are widely available at an affordable cost, techniques such as PCR-ELISA ASO typing will continue to have a role.
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Prostate-specific antigen (PSA) is present in serum in several forms, most importantly free PSA (FPSA) and PSA complexed to ␣ 1 -antichymotrypsin (1, 2 ) . These PSA forms are useful in assessing prostate disease (3) (4) (5) . When PSA is Ͼ10 g/L (ng/mL), the probability of prostate cancer is 50% (6 ); when PSA is between 4 and 10 g/L, the probability of prostate cancer is 25%. Patients in the latter range are usually recommended for biopsy, but here the low specificity leads to many unnecessary biopsies. The percentage of FPSA (%FPSA) is used to enhance specificity. The relative proportion of FPSA in serum may range from 5% to 50% (7 ), but a lower %FPSA is associated with higher probability of prostate cancer (8 ) .
Published guidelines for the clinical use of %FPSA have been contradictory because of differences in assay systems and standardization, study designs, patient populations, and the number of subjects enrolled (9 ) . A large well-controlled multicenter clinical trial was conducted to define a medically significant %FPSA cutpoint that would indicate the need for prostate biopsy. This report summarizes the assay performance from the largest clinical trial to date evaluating %FPSA in a patient population representative of those men in whom the test would be used in clinical practice. The data formed the basis for the Food and Drug Administration's approval of Hybritech's free PSA assays. Detailed clinical performance characteristics have been presented previously (10 ) .
The objective of this clinical trial was twofold: to evaluate the performance of Hybritech's Tandem-R free Clinical Chemistry 45, No. 10, 1999 
